Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Goodin

Showing results (11-20 of 203) with videos related to

Pageof 21
Sort By:
Neurology|September 27, 2006
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating eventDouglas S Goodin
Neuroepidemiology|February 2, 2000
The cladribine trial in secondary progressive MS: responseD S Goodin
Expert Opinion on Investigational Drugs|November 4, 2000
Therapeutic developments in multiple sclerosisD S Goodin
Neurology|July 1, 1991
The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical reviewD S Goodin
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2011
Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous roadDouglas S Goodin
Neurologic Clinics|August 1, 1985
Electrophysiologic evaluation of dementiaD S Goodin
International MS Journal|January 21, 2006
Evidence-based medicineD S Goodin
Neurology|October 13, 2006
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisDouglas S Goodin
Plos One|December 29, 2012
The genetic and environmental bases of complex human-disease: extending the utility of twin-studiesDouglas S Goodin
Seminars in Neurology|May 28, 2013
The use of interferon Beta and glatiramer acetate in multiple sclerosisDouglas S Goodin
Pageof 21

Showing results (11-20 of 203) with videos related to

Sort By:
Pageof 21
Neurology|September 27, 2006
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating eventDouglas S Goodin
Neuroepidemiology|February 2, 2000
The cladribine trial in secondary progressive MS: responseD S Goodin
Expert Opinion on Investigational Drugs|November 4, 2000
Therapeutic developments in multiple sclerosisD S Goodin
Neurology|July 1, 1991
The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical reviewD S Goodin
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2011
Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous roadDouglas S Goodin
Neurologic Clinics|August 1, 1985
Electrophysiologic evaluation of dementiaD S Goodin
International MS Journal|January 21, 2006
Evidence-based medicineD S Goodin
Neurology|October 13, 2006
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisDouglas S Goodin
Plos One|December 29, 2012
The genetic and environmental bases of complex human-disease: extending the utility of twin-studiesDouglas S Goodin
Seminars in Neurology|May 28, 2013
The use of interferon Beta and glatiramer acetate in multiple sclerosisDouglas S Goodin
Pageof 21